

Product datasheet for RC202922L1V

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

CD19 (NM_001770) Human Tagged ORF Clone Lentiviral Particle

Product data:

Product Type: Lentiviral Particles

Product Name: CD19 (NM 001770) Human Tagged ORF Clone Lentiviral Particle

Symbol: CD19

Synonyms: B4; CVID3

Mammalian Cell

Selection:

None

Vector: pLenti-C-Myc-DDK (PS100064)

 Tag:
 Myc-DDK

 ACCN:
 NM_001770

 ORF Size:
 1668 bp

ORF Nucleotide

OTI Disclaimer:

eotide

Sequence:

The ORF insert of this clone is exactly the same as(RC202922).

The molecular sequence of this clone aligns with the gene accession number as a point of reference only. However, individual transcript sequences of the same gene can differ through naturally occurring variations (e.g. polymorphisms), each with its own valid existence. This

clone is substantially in agreement with the reference, but a complete review of all prevailing

variants is recommended prior to use. More info

OTI Annotation: This clone was engineered to express the complete ORF with an expression tag. Expression

varies depending on the nature of the gene.

RefSeg: NM 001770.3

RefSeq Size: 1965 bp
RefSeq ORF: 1671 bp
Locus ID: 930

 UniProt ID:
 P15391

 Cytogenetics:
 16p11.2

Protein Families: Druggable Genome, Transmembrane

Protein Pathways: B cell receptor signaling pathway, Hematopoietic cell lineage, Primary immunodeficiency







MW:

61.1 kDa

Gene Summary:

This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]